| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/04/2001 | CN1067989C New compound with analgesic and local anaesthetic effect |
| 07/04/2001 | CN1067901C Drug for curing migraine and its preparing method |
| 07/03/2001 | US6255502 Pharmaceutical composition containing acid addition salt of basic drug |
| 07/03/2001 | US6255490 Treating disorders associated with changes in cholinergic activity; non-opiate based analgesic for moderate to severe pain equally or exceeding the potency of opiate analgesics, yet lacking addictive side effects |
| 07/03/2001 | US6255485 Purine inhibitors of protein kinases, G proteins and polymerases |
| 07/03/2001 | US6255471 CRFG-1b, a target and marker for chronic renal failure |
| 07/03/2001 | US6255468 MPROT12 polynucleotides and methods thereof |
| 07/03/2001 | US6255453 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 07/03/2001 | US6255346 Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholics and preventing the abuse of alcohol in healthy subjects |
| 07/03/2001 | US6255334 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
| 07/03/2001 | US6255329 Combined use of pramipexole and sertraline for the treatment of depression |
| 07/03/2001 | US6255327 Diphenyl-substituted heterocycles, processes for preparing them and their use as pharmaceutical compositions |
| 07/03/2001 | US6255325 Chronic, bolus administration of D-threo methylphenidate |
| 07/03/2001 | US6255319 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands |
| 07/03/2001 | US6255310 Psychological disorders; antidepressants |
| 07/03/2001 | US6255307 Pyrazine compounds |
| 07/03/2001 | US6255306 4-indole derivatives as serotonin agonists and antagonists |
| 07/03/2001 | US6255305 Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
| 07/03/2001 | US6255302 Nervous system, psychological disorders |
| 07/03/2001 | US6254899 Plant extract compositions, method of preparation, and pharmaceutical compositions containing them |
| 07/03/2001 | US6254887 Controlled release tramadol |
| 07/03/2001 | US6254865 Method of treating huntington's disease using HNT neurons |
| 07/03/2001 | US6254853 Drugs with carriers |
| 07/03/2001 | CA2214005C Process and crystal forms of 2-methyl-thieno-benzodiazepine |
| 07/03/2001 | CA2132512C Bioadhesive pharmaceutical composition used for the controlled release of active ingredient |
| 07/03/2001 | CA2098108C Water dispersible tablets |
| 07/03/2001 | CA2077641C Aqueous suspension preparation for injection, method for producing the same and use thereof for producing pain relief |
| 07/03/2001 | CA2012115C Iodinated somatostatins |
| 06/30/2001 | CA2293852A1 Procedure for preparing active plant extracts used to trap free radicals; the extracts and compounds and devices containing them |
| 06/29/2001 | CA2329576A1 Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-ht1d receptor selective antagonists |
| 06/28/2001 | WO2001046700A2 Sodium channels as targets for amyloid beta |
| 06/28/2001 | WO2001046699A1 INHIBITION OF βARRESTIN MEDIATED EFFECTS PROLONGS AND POTENTIATES OPIOID RECEPTOR-MEDIATED ANALGESIA |
| 06/28/2001 | WO2001046450A1 Replication incompetent herpes virus vectors |
| 06/28/2001 | WO2001046449A1 Replication incompetent herpes viruses for use in gene therapy |
| 06/28/2001 | WO2001046443A2 Proteases |
| 06/28/2001 | WO2001046398A2 Aspartyl proteases |
| 06/28/2001 | WO2001046394A2 Mammalian protein phosphatases |
| 06/28/2001 | WO2001046392A2 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | WO2001046263A1 Novel compounds |
| 06/28/2001 | WO2001046258A2 Transporters and ion channels |
| 06/28/2001 | WO2001046256A2 Vesicle trafficking proteins |
| 06/28/2001 | WO2001046255A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046231A2 Polynucleotides and polypeptides encoded thereby |
| 06/28/2001 | WO2001046206A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046205A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046204A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | WO2001046203A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | WO2001046198A2 Nonpeptide kappa opioid receptor antagonists |
| 06/28/2001 | WO2001046196A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | WO2001046195A1 Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
| 06/28/2001 | WO2001046192A1 SPIRO COMPOUNDS USEFUL AS OPIOID δ RECEPTOR AGONIST |
| 06/28/2001 | WO2001046191A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | WO2001046186A1 Benzofuran derivatives |
| 06/28/2001 | WO2001046184A1 3-thiazol-4-yl-pyprolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046183A1 SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-α LEVELS |
| 06/28/2001 | WO2001046181A1 Indole derivatives for the treatment of depression and anxiety |
| 06/28/2001 | WO2001046179A1 Piperidine derivatives and their use as serotonin receptor antagonists |
| 06/28/2001 | WO2001046177A1 Benzofuran derivatives |
| 06/28/2001 | WO2001046176A2 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | WO2001046174A1 Novel compounds |
| 06/28/2001 | WO2001046173A1 SELECTIVE iGLUR5 RECEPTOR ANTAGONISTS |
| 06/28/2001 | WO2001046172A1 Pyrazole cyclic amp-specific pde inhibitors |
| 06/28/2001 | WO2001046171A1 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 06/28/2001 | WO2001046170A1 Amidine derivatives which are inhibitors of nitric oxide synthase |
| 06/28/2001 | WO2001046168A1 Tryptase inhibitors |
| 06/28/2001 | WO2001046166A2 Partially saturated calcium channel blockers |
| 06/28/2001 | WO2001046146A1 New modulators of dopamine neurotransmission |
| 06/28/2001 | WO2001046145A1 New modulators of dopamine neurotransmission |
| 06/28/2001 | WO2001046144A1 New modulators of dopamine neurotransmission |
| 06/28/2001 | WO2001046136A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | WO2001046128A2 Tryptase inhibitors |
| 06/28/2001 | WO2001045749A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | WO2001045739A1 Remedies and/or preventives for nervous system disorders |
| 06/28/2001 | WO2001045722A1 Somnogenic activity of non-pathogenic lactic acid bacteria |
| 06/28/2001 | WO2001045715A2 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 06/28/2001 | WO2001045714A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045711A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | WO2001045709A1 Substituted piperazine and piperidine calcium channel blockers |
| 06/28/2001 | WO2001045708A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| 06/28/2001 | WO2001045703A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | WO2001045700A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | WO2001045694A1 Urotensin-ii receptor antagonists |
| 06/28/2001 | WO2001045692A1 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 06/28/2001 | WO2001045689A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 06/28/2001 | WO2001045687A2 Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
| 06/28/2001 | WO2001045686A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045685A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045684A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045683A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045682A2 Formulations of adenosine a1 agonists |
| 06/28/2001 | WO2001045677A1 Process for producing nanometer particles by fluid bed spray-drying |
| 06/28/2001 | WO2001045674A1 Process for producing nanometer particles by fluid bed spray-drying |
| 06/28/2001 | WO2001045671A2 Suspension comprising oxcarbazepine |
| 06/28/2001 | WO2001045663A2 USE OF AROMATIC POLYCYCLIC COMPOUNDS AS ACTIVATORS OF PPARs-TYPE RECEPTORS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
| 06/28/2001 | WO2001045637A2 Novel 4(piperazinyl (8-quinolinyl)metyl)benzamides |
| 06/28/2001 | WO2001045509A1 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs |
| 06/28/2001 | WO2001045483A2 Method for the preparation of pure citalopram |
| 06/28/2001 | WO2001009122A3 Serotonergic benzofurans |
| 06/28/2001 | WO2001002561A3 Mammalian calcium channels and related probes, cell lines and methods |
| 06/28/2001 | WO2001002380A8 Antipsychotic cyclic n-aralkyl amines |